Compare FLNG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | NTLA |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2019 | 2016 |
| Metric | FLNG | NTLA |
|---|---|---|
| Price | $31.00 | $10.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 23 |
| Target Price | ★ $23.00 | $20.02 |
| AVG Volume (30 Days) | 347.0K | ★ 4.3M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.14 | $62.75 |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $24.00 | $7.95 |
| 52 Week High | $33.40 | $28.24 |
| Indicator | FLNG | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 53.78 | 32.00 |
| Support Level | $28.71 | $8.59 |
| Resistance Level | $31.31 | $15.52 |
| Average True Range (ATR) | 0.83 | 0.80 |
| MACD | 0.06 | -0.35 |
| Stochastic Oscillator | 74.73 | 10.20 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.